NINDS

Congress Passes Bills Making Major Investments in Alzheimer’s

Retrieved on: 
Saturday, March 23, 2024
Congress, Medical imaging, Caregiver, Health equity, DSM-IV codes, Research, National Institute on Aging, National coverage determination, Investment, CDC, NINDS, Language, Dementia, NIA, Medicare, NCD, CMS, Pharmaceutical industry

WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.

Key Points: 
  • WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.
  • “We are thrilled to witness Congress’s steadfast 12-year commitment to Alzheimer’s research, despite ongoing budget restraints,” said UsAgainstAlzheimer’s chair and co-founder George Vradenburg.
  • UsAgainstAlzheimer’s worked to include language encouraging diversity in clinical trials, and the establishment of a brain health equity initiative to improve the integration of brain health into primary care, particularly within underrepresented communities.
  • The bill also encourages the National Institute of Biomedical Imaging and Bioengineering to collaborate with National Institute of Aging (NIA) and The National Institute of Neurological Disorders and Stroke (NINDS) to develop new technologies that could discover the earliest biological events that lead to Alzheimer’s disease and related dementias.

The Brain Aneurysm Foundation and Families of Individuals Impacted by the Disease Join Forces to Advocate for Increased Research Funding and Education

Retrieved on: 
Tuesday, March 19, 2024
Research, Organization, Myenteric plexus, Prevalence, Aneurysm, Disease, Intracranial aneurysm, Caregiver, Education, DSM-IV codes, Biomarker, Policy, Patient, University, Death, Risk, Rupture, Tutino, Survivor, Subarachnoid hemorrhage, NINDS, Biomedical sciences, Murder of Ellie Gould, Bangladesh Technical Education Board, Family, Physician, Health, Pharmaceutical industry

HANOVER, Mass., March 19, 2024 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today joined with caregivers, survivors, researchers, and physicians from across the U.S. to advocate for greater funding and to increase awareness of brain aneurysms and the long-term impact they can have on individuals and their families.

Key Points: 
  • Worldwide, there are close to 500,000 deaths each year from brain aneurysms, half of which occur in people under the age of 50.
  • The family's extensive work to honor Katelyn, who died just months before her planned wedding, has led to their involvement in supporting increased funding for critical research.
  • 902 and S. 895), which would provide dedicated research for aneurysm prevention and improve the long-term outcomes for aneurysm survivors.
  • "Brain scans can be cost prohibitive and are often not recommended by a physician unless there is a family history of the disease.

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Retrieved on: 
Monday, February 26, 2024
NINDS, NCI, Immunotherapy, NIH, National Cancer Institute, Radiation, PP2A, Patent, Patient, CRADA, Development, DSM-IV codes, Research, Cancer, Pharmaceutical industry

PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).

Key Points: 
  • PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).
  • The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
  • The agreement reinforces our dedication to pioneering research and delivering innovative solutions to patients battling cancer," he added.
  • The licensed patent rights provide LIXTE with a unique opportunity to explore and develop novel combination therapies that can potentially transform the landscape of cancer treatment.

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs

Retrieved on: 
Thursday, February 22, 2024
ACT, Massachusetts General Hospital, Mass, Master of Science, NINDS, Bangladesh Technical Education Board, Neuromuscular disease, ALS, CNM, Doctor of Philosophy, NIH, FDA, Record, Hospital, Risk, Natural history, EAPS, Multiple sclerosis, Safety, Data, Patient, Survival, Disease, Harvard Medical School, Columbia University, EAP, Mortality, DSM-IV codes, Pharmaceutical industry

CNM-Au8 30 mg treatment was well-tolerated, without a single serious adverse event attributed to CNM-Au8, and no significant safety findings reported.

Key Points: 
  • CNM-Au8 30 mg treatment was well-tolerated, without a single serious adverse event attributed to CNM-Au8, and no significant safety findings reported.
  • A pooled survival analysis of EAP participants treated with CNM-Au8 30 mg was compared to two independent datasets derived from PRO-ACT and the ALS/MND Natural History Consortium.
  • The EAP dataset was comprised of 256 participants with ALS of which 220 EAP participants had all baseline values available for matching.
  • The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Clene supported the first EAP (EAP01) launched in 2019.

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Retrieved on: 
Thursday, February 15, 2024
NINDS, Central nervous system, Rush University Medical Center, Giant axonal neuropathy, GM2, Rett syndrome, CNS, IP, GAN, IND, AAV, DSM-IV codes, Pharmaceutical industry

DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.

Key Points: 
  • DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.
  • Taysha has been working to find ways to advance its deprioritized programs.
  • On November 13, 2023, Taysha terminated its existing loan and security agreement and entered into a new loan and security agreement that provides consent to allow the Company to transfer intellectual property (IP) for several deprioritized programs to third parties in a more efficient manner.
  • “Today’s announcement demonstrates meaningful progress to advance important development work for several deprioritized programs.

RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

Retrieved on: 
Tuesday, February 13, 2024
Therapy, NINDS, RespireRx, GABAA, NIH, Neuropathic pain, Epilepsy, Addiction, Neuron, Narcotic, Female, Rat, OTC Markets Group, Drug discovery, Analgesic, Disability studies, Interim, University, PSPP, Pain management, Chronic pain, Research fellow, Patient, Heart, Initiative, Male, Hypoventilation, IND, DRS, Laboratory, Research, Pharmaceutical industry

Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.

Key Points: 
  • Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.
  • The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models.
  • These observations were made with both male and female rats in two measures each, in models of post-incision pain and spinal nerve ligation-induced persistent neuropathic pain.
  • These data trigger the advancement of KRM-II-81 within the NIH PSPP program where additional disease-specific pain models will be evaluated.

Global Narcolepsy Drugs Market Research Report 2024: Pipeline Analysis, Key Company Profiles and Recent Developments 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 30, 2024
General Health, Pharmaceutical, Health, Narcolepsy, Jazz Pharmaceuticals, CIII, FDA, Central nervous system, Somnolence, Consciousness, Quality of life, DSM-IV codes, Mazindol, Takeda Pharmaceutical Company, Tobacco, Organization, Cataplexy, EDS, Prevalence, American Academy, CNS, Selective serotonin reuptake inhibitor, Growth, Patient, Diagnosis, Marketing, Disease, U.S. FDA, NINDS, Research, Therapy, Teva Pharmaceuticals, Investment, Avadel Pharmaceuticals, European Medicines Agency, Pharmaceutical industry

The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global narcolepsy drugs market has witnessed significant growth in recent years owing to the rising prevalence of narcolepsy and increased awareness about the condition.
  • Latin America and Middle East & Africa are competing closely to grab the maximum share of the global narcolepsy drugs market.
  • Global Narcolepsy Drugs Market - Key Company Profiles, Recent Developments, Financial Insights

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies

Retrieved on: 
Monday, January 29, 2024
Hope, Development, Woman, Medical Research Council, Patient, NINDS, Fatigue, CRADA, Intramural sports, Ryanodine receptor 1, Journal, Muscle contraction, Safety, Disease, Muscle weakness, NIH, DSM-IV codes, RYR1, Publication, Research, Bangladesh Technical Education Board, Pharmacokinetics, Pharmaceutical industry

The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).

Key Points: 
  • The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).
  • These results warrant further development of ARM210 as a potential disease modifying treatment for RYR1-RM in a randomized, placebo-controlled Phase 2 trial.
  • We look forward to the next stages in the development of this important drug.”
    Further information about this Phase 1b trial can be found online at: https://clinicaltrials.gov/study/NCT04141670 .
  • Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial, Todd et al, eClinicalMedicine https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00012-9/fulltext

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies

Retrieved on: 
Monday, January 29, 2024
Hope, Development, Woman, Medical Research Council, Patient, NINDS, Fatigue, CRADA, Intramural sports, Ryanodine receptor 1, Journal, Muscle contraction, Safety, Disease, Muscle weakness, NIH, DSM-IV codes, RYR1, Publication, Research, Bangladesh Technical Education Board, Pharmacokinetics, Pharmaceutical industry

The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).

Key Points: 
  • The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).
  • These results warrant further development of ARM210 as a potential disease modifying treatment for RYR1-RM in a randomized, placebo-controlled Phase 2 trial.
  • We look forward to the next stages in the development of this important drug.”
    Further information about this Phase 1b trial can be found online at: https://clinicaltrials.gov/study/NCT04141670 .
  • Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial, Todd et al, eClinicalMedicine https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00012-9/fulltext

Narcolepsy Drugs Market, Size, Global Forecast 2024-2030: Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, December 29, 2023
Health, Pharmaceutical, Novartis, Teva Pharmaceuticals, Quality of life, Sodium oxybate, Food, Risk, Drug development, Takeda Pharmaceutical Company, Roche, Research, Cataplexy, FDA, Instability, Prevalence, NINDS, Incidence, Mazindol, GHB, Stimulant, EDS, NMPA, Narcolepsy, Tobacco, DSM-IV codes, Investment, Patient, Diagnosis, Organization, Somnolence, Neurological disorder, Pharmaceutical industry

The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Narcolepsy Drugs Market is poised for substantial growth, with a projected value of US$5.95 billion by 2030
    Several factors contribute to the expansion of the narcolepsy drugs market.
  • The Narcolepsy Drugs Market is expected to grow steadily, with a compound annual growth rate (CAGR) of 8.01% from 2023 to 2030.
  • Combined, these elements make the U.S. narcolepsy drugs market a leader in global healthcare.